Heritage Announces the Launch of Etomidate for Injection

East Brunswick, NJ, May 14, 2018. Heritage Pharmaceuticals Inc. (“Heritage”) announced the immediate availability of Etomidate Injection, USP, in 20mg/10mL and 40mg/20mL strengths. This launch adds to Heritage’s growing portfolio of generic injectable products. Etomidate is the AP rated generic equivalent to the general anesthetic drug Amidate™. It is indicated for the induction of general anesthesia. According to IMS data for the twelve-months ended May 2018, the U.S. market for Etomidate injection approximated $8.3 million.

Download Press Release